Literature DB >> 21169474

Control of carcinoid syndrome with everolimus.

J Capdevila1, I Díez Miranda2, G Obiols3, J Tabernero4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21169474     DOI: 10.1093/annonc/mdq670

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.

Authors:  Antongiulio Faggiano; Pasqualino Malandrino; Roberta Modica; Daniela Agrimi; Maurizio Aversano; Vincenzo Bassi; Ernesto A Giordano; Valentina Guarnotta; Francesco A Logoluso; Erika Messina; Vincenzo Nicastro; Vincenzo Nuzzo; Marcello Sciaraffia; Annamaria Colao
Journal:  Oncologist       Date:  2016-04-06

Review 2.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 3.  Refractory carcinoid syndrome: a review of treatment options.

Authors:  Rachel P Riechelmann; Allan A Pereira; Juliana F M Rego; Frederico P Costa
Journal:  Ther Adv Med Oncol       Date:  2016-11-02       Impact factor: 8.168

4.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

5.  Symptomatic Control of Neuroendocrine Tumours with Everolimus.

Authors:  Hannah E Bainbridge; Emmanuel Larbi; Gary Middleton
Journal:  Horm Cancer       Date:  2015-08-06       Impact factor: 3.869

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.